ABSTRACT
Background: Atorvastatin is prescribed for the primary and the secondary prevention of coronary artery diseases. A wide variation in inter-individual statin response suggests that genetic differences may contribute to this variation. This study investigated the association of ABCB1 [C3435T] and ABCC1 [G2012T] polymorphisms with clinical response to atorvastatin in Iranian primary hyperlipidemic patients
Methods: Individuals [n=179] with primary hypercholesterolemia were enrolled, and peripheral blood samples were collected. Genotyping of two polymorphisms were performed by amplification refractory mutation system PCR
Results: Following four weeks of treatment, a significant reduction of LDL-C was observed in variant groups [CT+TT] of ABCB1 [P=0.018] and wild-type group [GG] of ABCC1 genes [P=0.029]. Logistic regression analysis revealed a significant difference between male and female responses to 10 mg/day atorvastatin [P=0.004, odds ratio=0.2, CI 95%=0.06-0.6]
Conclusion: Our finding indicated that these polymorphisms may be attributed to LDL-C serum levels in the primary hypercholesterolemia patients receiving atorvastatin